Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
Part of paid clinical trials in Bay City, Michigan.
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Study ID
- NCT02178163
- Status
- Recruiting
Conditions
- Recurrent Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- cytology specimen collection procedure — OTHERCorrelative studies
- laboratory biomarker analysis — OTHERCorrelative studies
Study Details
This research trial studies comprehensive genomic analysis in tissue samples from patients with non-small cell lung cancer that has come back or is stage IV. Comprehensive genomic analysis may identify specific gene mutations (changes in deoxyribonucleic acid \[DNA\]) and help doctors to tailor treatment to target the specific mutations.
Key Dates
- Start date
- Aug 1, 2014
- Status verified
- Jul 2025
- Primary completion
- Jul 31, 2027
- Completion
- Jul 31, 2027
Study Design
- Enrollment
- 1,020 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- OTHER
Arms
- Experimental: Ancillary-Correlative (comprehensive genomic analysis)Patients undergo collection of tissue samples for genomic analysis via mass spectrometry, PCR, and microarray. Based on the results of the genomic analysis, patients may begin therapy.
Primary Outcome Measure
Proportion of patients receiving therapy based on genomic analyses among all eligible patients [ Time Frame: Up to 21 days ]
Central Contacts
- Gerold Bepler, M.D.(313) 576-8665
Locations (11)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| KCI at McLaren Bay Region | Bay City | Michigan | 48708 | 800-527-6266 |
| KCI at Mclaren Bloomfield Hills | Bloomfield Hills | Michigan | 48302 | 1800-527-6266 |
| KCI At McLaren Clarkston | Clarkston | Michigan | 48346 | 1-800-527-6266 |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201 | Gerold Bepler, M.D., PhD. (PRINCIPAL_INVESTIGATOR) Ammar Sukari, M.D. (SUB_INVESTIGATOR) Hirva Mamdani, M.D. (SUB_INVESTIGATOR) Jonathan D. Abramson, M.D. (SUB_INVESTIGATOR) Shalini Thoutreddy, M.D. (SUB_INVESTIGATOR) Samir Alsawah, M.D. (SUB_INVESTIGATOR) Sai Bikkina, M.D. (SUB_INVESTIGATOR) Rana Bilbeisi, M.D, (SUB_INVESTIGATOR) Elena Coppola, M.D. (SUB_INVESTIGATOR) Salman Fateh, M.D. (SUB_INVESTIGATOR) Sandeep Grewal, M.D. (SUB_INVESTIGATOR) Youssef Hanna, M.D. (SUB_INVESTIGATOR) Christian Hyde, M.D. (SUB_INVESTIGATOR) Frank Knechtl, M.D. (SUB_INVESTIGATOR) Cheryl Kovalski, M.D. (SUB_INVESTIGATOR) Elizabeth Layhe, M.D. (SUB_INVESTIGATOR) Mohammed Masri, M.D. (SUB_INVESTIGATOR) Seraphim Pallas, M.D. (SUB_INVESTIGATOR) Anup Lal, M.D. (SUB_INVESTIGATOR) Dipesh Uprety, M.D. (SUB_INVESTIGATOR) Brooke Spencer (Trotter), M.D. (SUB_INVESTIGATOR) Numan Fateh, M.D. (SUB_INVESTIGATOR) Borys Hrinczenko, M.D. (SUB_INVESTIGATOR) Daniel Isaac, D.O. (SUB_INVESTIGATOR) Jatin Rana, M.D. (SUB_INVESTIGATOR) Ashley Matusz-Fisher, M.D. (SUB_INVESTIGATOR) Faras Alsawah, M.D. (SUB_INVESTIGATOR) Tarik Hadid, M.D. (SUB_INVESTIGATOR) Irene Connolly, M.D. (SUB_INVESTIGATOR) Orimisan Adekolujo, M.D. (SUB_INVESTIGATOR) Kalub Fedak, M.D. (SUB_INVESTIGATOR) |
| KCI at McLaren Flint | Flint | Michigan | 48532 | 1-800-527-6266 |
| KCI at McLaren Greater Lansing, Mid Michigan Physicians | Lansing | Michigan | 48910 | (517) 975-9500 |
| KCI at McLaren Lapeer Region | Lapeer | Michigan | 48446 | 1-800-527-6266 |
| KCI at McLaren Macomb | Mount Clemens | Michigan | 48043 | 1-800-527-6266 |
| KCI at McLaren Central Michigan | Mount Pleasant | Michigan | 48858 | 1-800-527-6266 |
| KCI at Northern Michigan | Petoskey | Michigan | 49770 | 1-800-527-6266 |
| KCI at McLaren Port Huron | Port Huron | Michigan | 48060 | 800-527-6266 |
Find similar trials in Bay City, MI
Related Studies
- Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung CancerRecruiting · Ohio State University Comprehensive Cancer Center · Columbus, Ohio
- Patient-centered, Optimal Integration of Survivorship and Palliative CareRecruiting · Massachusetts General Hospital · Boston, Massachusetts
- A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung CancerPHASE1/PHASE2 · Recruiting · Iovance Biotherapeutics, Inc. · Los Angeles, California
- Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLCPHASE1 · Recruiting · H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida